ArticleWorld journal of surgical oncology2022
Analyzing the role of reoperation in recurrent glioblastoma: a 15-year retrospective study in a single institution.
Article in World journal of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Surgical treatment of recurrent glioblastoma: a multicenter perspective from the Italian society of neurosurgery (SINchNeurosurgical review · 2026Pooled it
- Timing and Benefit of Early Versus Delayed Reoperation in Recurrent Glioblastoma: A Systematic Review and Meta-Analysis of Survival and Functional Outcomes.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Current trends in reoperation for recurrent glioblastoma: a meta-analysis (2007-2023).Journal of neuro-oncology · 2025Pooled it
- The impact of intraoperative mapping during re-resection in recurrent gliomas: a systematic review.Journal of neuro-oncology · 2025Pooled it
- Prognostic impact of second surgical resection in IDH wildtype recurrent glioblastoma following chemo-radiation therapy: a propensity score analysis cohort study.Journal of neuro-oncology · 2025Article
- Fn14-Targeted Gold Nanorods for Augmenting Laser Thermal Therapy for High-Grade Gliomas.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Repeat Resection for Recurrent Glioblastoma in the WHO 2021 Era: A Longitudinal Matched Case-Control Study.Brain sciences · 2025Article
- Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology.Pharmaceutics · 2025Review
- Association between serum response factor, microvascular density, and postoperative recurrence in glioma patients.American journal of translational research · 2025Article
- Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers.International journal of molecular sciences · 2024Article
- Recurrent Glioblastoma-Molecular Underpinnings and Evolving Treatment Paradigms.International journal of molecular sciences · 2024Review
- Evidence That a Peptide-Drug/p53 Gene Complex Promotes Cognate Gene Expression and Inhibits the Viability of Glioblastoma Cells.Pharmaceutics · 2024Article
- Second surgery for relapsed glioblastoma: an observational study on criteria for patient selection in real life.Future oncology (London, England) · 2024Observational
- Surgical Management and Advances in the Treatment of Glioma.Seminars in neurology · 2023Review
- Intraoperative 5-aminolevulinic acid fluorescence-guided aspirate tissue monitoring in high-grade glioma surgery: The first-in-human study on clinical performance and safety.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple treatment options at glioblastoma progression exist, including reintervention, reirradiation, additional systemic therapy, and novel strategies. No alternative has been proven to be superior in terms of postprogression survival (PPS). A second surgery has shown conflicting evidence in the literature regarding its prognostic impact, possibly affected by selection bias, and might benefit a sparse subset of patients with recurrent glioblastoma. The present study aims to determine the prognostic influence of salvage procedures in a cohort of patients treated in the same institution over 15 years.
methodsThree hundred and fifty patients with confirmed primary glioblastoma diagnosed and treated between 2005 and 2019 were selected. To examine the role of reoperation, we intended to create comparable groups, previously excluding all diagnostic biopsies and patients who were not actively treated after the first surgery or at disease progression. Uni- and multivariate Cox proportional hazards regression models were employed, considering reintervention as a time-fixed or time-dependent covariate. The endpoints of the study were overall survival (OS) and PPS.
resultsAt progression, 33 patients received a second surgery and 84 were treated with chemotherapy only. Clinical variables were similar among groups. OS, but not PPS, was superior in the reintervention group. Treatment modality had no impact in our multivariate Cox regression models considering OS or PPS as the endpoint.
conclusionsThe association of reoperation with improved prognosis in recurrent glioblastoma is unclear and may be influenced by selection bias. Regardless of our selective indications and high gross total resection rates in second procedures, we could not observe a survival advantage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.